155 related articles for article (PubMed ID: 8490179)
1. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.
Corradini P; Ladetto M; Voena C; Palumbo A; Inghirami G; Knowles DM; Boccadoro M; Pileri A
Blood; 1993 May; 81(10):2708-13. PubMed ID: 8490179
[TBL] [Abstract][Full Text] [Related]
2. N- and K-ras oncogenes in plasma cell dyscrasias.
Corradini P; Ladetto M; Inghirami G; Boccadoro M; Pileri A
Leuk Lymphoma; 1994 Sep; 15(1-2):17-20. PubMed ID: 7858496
[TBL] [Abstract][Full Text] [Related]
3. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
Matozaki S; Nakagawa T; Nakao Y; Fujita T
Kobe J Med Sci; 1991 Feb; 37(1):35-45. PubMed ID: 1921261
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
Corradini P; Inghirami G; Astolfi M; Ladetto M; Voena C; Ballerini P; Gu W; Nilsson K; Knowles DM; Boccadoro M
Leukemia; 1994 May; 8(5):758-67. PubMed ID: 8182933
[TBL] [Abstract][Full Text] [Related]
5. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
Martín P; Santón A; García-Cosío M; Bellas C
Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
[TBL] [Abstract][Full Text] [Related]
6. N-ras and p53 gene mutations are very rare events in multiple myeloma.
Yasuga Y; Hirosawa S; Yamamoto K; Tomiyama J; Nagata K; Aokia N
Int J Hematol; 1995 Aug; 62(2):91-7. PubMed ID: 8590778
[TBL] [Abstract][Full Text] [Related]
7. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
Bezieau S; Devilder MC; Avet-Loiseau H; Mellerin MP; Puthier D; Pennarun E; Rapp MJ; Harousseau JL; Moisan JP; Bataille R
Hum Mutat; 2001 Sep; 18(3):212-24. PubMed ID: 11524732
[TBL] [Abstract][Full Text] [Related]
8. p53 and RAS gene mutations in multiple myeloma.
Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
[TBL] [Abstract][Full Text] [Related]
9. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
[TBL] [Abstract][Full Text] [Related]
10. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.
Kalakonda N; Rothwell DG; Scarffe JH; Norton JD
Blood; 2001 Sep; 98(5):1555-60. PubMed ID: 11520807
[TBL] [Abstract][Full Text] [Related]
11. Oncogenes in multiple myeloma: point mutation of N-ras.
Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
[TBL] [Abstract][Full Text] [Related]
12. Ras proto-oncogene activation in liver and lung tumors from B6C3F1 mice exposed chronically to methylene chloride.
Devereux TR; Foley JF; Maronpot RR; Kari F; Anderson MW
Carcinogenesis; 1993 May; 14(5):795-801. PubMed ID: 8504471
[TBL] [Abstract][Full Text] [Related]
13. Ras oncogene mutation in multiple myeloma.
Neri A; Murphy JP; Cro L; Ferrero D; Tarella C; Baldini L; Dalla-Favera R
J Exp Med; 1989 Nov; 170(5):1715-25. PubMed ID: 2681517
[TBL] [Abstract][Full Text] [Related]
14. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Liu P; Leong T; Quam L; Billadeau D; Kay NE; Greipp P; Kyle RA; Oken MM; Van Ness B
Blood; 1996 Oct; 88(7):2699-706. PubMed ID: 8839865
[TBL] [Abstract][Full Text] [Related]
15. The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.
Millar BC; Bell JB; Barfoot R; Everard M
Br J Cancer; 1995 Feb; 71(2):259-64. PubMed ID: 7841038
[TBL] [Abstract][Full Text] [Related]
16. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
[TBL] [Abstract][Full Text] [Related]
17. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies.
Mateos MV; Garcia-Sanz R; López-Pérez R; Balanzategui A; González MI; Fernández-Calvo J; Moro MJ; Hernández J; Caballero MD; González M; San Miguel JF
Hematol J; 2001; 2(3):146-9. PubMed ID: 11920239
[TBL] [Abstract][Full Text] [Related]
18. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas.
Challen C; Guo K; Collier JD; Cavanagh D; Bassendine MF
J Hepatol; 1992 Mar; 14(2-3):342-6. PubMed ID: 1323601
[TBL] [Abstract][Full Text] [Related]
19. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ;
Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420
[TBL] [Abstract][Full Text] [Related]
20. Lack of BCL10 mutations in multiple myeloma and plasma cell leukemia.
Shih LY; Fu JF; Shurtleff SA; Morris SW; Downing JR
Genes Chromosomes Cancer; 2001 Apr; 30(4):402-6. PubMed ID: 11241793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
